(MedPage Today) — The investigational cell therapy deramiocel slowed upper limb functional decline in boys and young men with Duchenne muscular dystrophy, data from the phase III HOPE-3 trial showed.
At 12 months, the mean percent change from…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
